Faculty Opinions recommendation of Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

2012 ◽  
Author(s):  
Severine Vermeire
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Active Ulcerative Colitis ◽  
Janus Kinase Inhibitor

scholarly journals Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2011 ◽  
Vol 140 (5) ◽  
pp. S-110 ◽  
Author(s):  
William J. Sandborn ◽  
Subrata Ghosh ◽  
Julian Panes ◽  
Ivana Vranic ◽  
Chinyu Su ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Janus Kinase Inhibitor ◽  
Phase 2 Study

scholarly journals Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2012 ◽  
Vol 367 (7) ◽  
pp. 616-624 ◽  
Author(s):  
William J. Sandborn ◽  
Subrata Ghosh ◽  
Julian Panes ◽  
Ivana Vranic ◽  
Chinyu Su ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Active Ulcerative Colitis ◽  
Janus Kinase Inhibitor

scholarly journals Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

2018 ◽  
Vol 12 (10) ◽  
pp. 1158-1169 ◽  
Author(s):  
Bruce E Sands ◽  
William J Sandborn ◽  
Brian G Feagan ◽  
Gary R Lichtenstein ◽  
Hongyan Zhang ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Phase 2 ◽  
Janus Kinase Inhibitor ◽  
Severe Ulcerative Colitis ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document